DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Analysts

DBV Technologies S.A. (NASDAQ:DBVT) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $35.3750.

DBVT has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, December 8th. Citizens Jmp lifted their price target on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a report on Wednesday.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently made changes to their positions in DBVT. Vivo Capital LLC acquired a new position in DBV Technologies during the second quarter worth about $9,659,000. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies during the 2nd quarter valued at approximately $340,000. Millennium Management LLC boosted its stake in shares of DBV Technologies by 26.1% during the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after acquiring an additional 69,849 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $220,000. Finally, Octagon Capital Advisors LP purchased a new position in DBV Technologies in the 2nd quarter valued at approximately $9,315,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $21.52 on Friday. The stock has a fifty day moving average price of $15.23 and a 200 day moving average price of $11.72. DBV Technologies has a 1-year low of $2.74 and a 1-year high of $26.18. The company has a market cap of $864.24 million, a PE ratio of -4.16 and a beta of -1.10.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.